Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-06-02
1998-05-05
Draper, Garnette D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 8, 514 12, 514 21, 424851, A61K 3816
Patent
active
057474443
ABSTRACT:
Medicaments and methods of using the same are disclosed for treating or preventing diseases resulting from undesirable cell adhesion of IL-1 receptor positive cells to biological materials, particular to endothelial cells, or autoimmune related diseases, preferably graft versus host disease, or IL-1 dependent cancers.
REFERENCES:
patent: 5011778 (1991-04-01), Newman et al.
patent: 5075222 (1991-12-01), Hannum et al.
patent: 5180812 (1993-01-01), Dower et al.
patent: 5359032 (1994-10-01), Dayer et al.
patent: 5455330 (1995-10-01), Haskill et al.
Carter, et al., "Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein," Nature 344:633-648 (Apr. 12, 1990).
Cominelli, et al., "Interleukin 1 (IL-1) Gene Expression, Synthesis, and Effect of Specific IL-1 Receptor Blockade in Rabbit Immune Complex Colitis," J. Clin. Invest., 86:972-980 (Sep. 1990).
Dinarello, et al., "Multiple Biological Activities of Human Recombinant Interleukin 1," J. Clin. Invest., 77:1734-1739 (Jun. 1986).
Eisenberg, et al., "Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist," Nature, 343:341-346, (Jan. 25, 1990).
Fanslow, et al., "Regulation of Alloreactivity in Vivo by a Soluble Form of the Interleukin-1 Receptor," Science, 248:739-742, (May 1990).
Gosset, et al., "Production of an Interleukin-1 Inhibitor Factor by Human Alveolar Macrophages from Normals and Allergic Asthmatic Patients," Am. Rev. Respir. Dis., 138:40-46 (1988).
Gershenwald, et al., "Interleukin 1 receptor blockade attenuates the host inflammatory response," Proc. Natl. Acad. Sci. USA, 87:4966-4970 (Jul. 1990).
Hannum, et al., "Interleukin-1 receptor antagonist activity of a human interluekin-1 inhibitor," Nature, 343:336-339 (Jan. 25, 1990).
Maliszewski, et al., "Cytokine Receptors and B Cell Functions--1. Recombinant Soluble Receptors Specifically Inhibit IL-1- and IL-4-Induced B Cell Activities in Vitro," The Journal of Immunology, 144:3028-3033, No. 8 (Apr. 15, 1990).
Oppenhiem, et al., "There is More Than One Interleukin 1," Immunology Today, Reviews, 7:45-56 No. 2 (1986).
Palaszynski, "Synthetic C-Terminal Peptide of IL-1 functions as a Binding Domain As Well As An Antagonist For The IL-1 Receptor," Biochemical and Biophysical Research Communications, 147:204-211, No. 1 (Aug. 31, 1987).
Seckinger, et al., "A Urine Inhibitor of Interluekin 1 Activity Affects Both Interleukin 1.alpha. and 1.beta. But Not Tumor Necrosis Factor.alpha.," The Journal of Immunology, 139:1541-1545, No. 5 (Sep. 1, 1987).
Simpson, et al., "Reduction of Experimental Canine Myocardial Reperfusion Injury by a Monoclonal Antibody (Anti-Mol, Anti-CD11b) That Inhibits Leukocyte Adhesion," J. Clin. Invest., 81:624-629 (Feb. 1988).
Dorland's Illustrated Medical Dictionary, 24th Ed., W.B. Saunders Company, Philadelphia, PA., p. 760, defining "ischemia," (1965).
Vedder, et al., "A Monoclonal Antibody to he Adherence-promoting Leukocyte Glycoprotein, CD18, Reduces Organ Injury and Improves Survival from Hemorrhagic Shock and Resuscitation in Rabbits," J. Clin. Invest., 81:939-944 (1988).
Cotran, et al., "Induction and Detection of a Human Endothelial Activation Antigen In Vivo," Brief Definitive Report, J. Exp. Med. 164: 661-666, (Aug. 1986).
Buchan, et al., "Interleukin-1 and tumor necrosis factor mRNA expression in rheimatoid arthritis: prolonged production of IL-1.alpha.," Clin. Exp. Immunol. 73:449-455 (Mar. 1988).
Haskill John Stephen
Ralph Peter
Blackburn Robert P.
Chiron Corporation
Draper Garnette D.
Pochopien Donald J.
Savereide Paul B.
LandOfFree
Method of treating graft-versus-host disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating graft-versus-host disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating graft-versus-host disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-54409